Who is sponsoring NCT03529656?

NCT03529656 is sponsored by Asan Medical Center.

What drugs are being tested in NCT03529656?

Interventions in NCT03529656: Early rehabilitation program for liver transplantation.

What condition does NCT03529656 study?

NCT03529656 studies ICU-acquired Weakness.

Is NCT03529656 still recruiting?

NCT03529656 is currently completed. Last updated 18 May 2018.

Last reviewed 2018-05-18 · How we verify

NCT03529656

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Early Rehabilitation Program in Post-LT Pts

Completed NA Last updated 18 May 2018

What this trial tests

NA trial testing Early rehabilitation program for liver transplantation in ICU-acquired Weakness in 236 participants. Completed in 31 March 2017.

Timeline

1 October 2014

Primary endpoint
31 March 2016

31 March 2017

Quick facts

Lead sponsor	Asan Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	236
Start date	1 October 2014
Primary completion	31 March 2016
Estimated completion	31 March 2017

Drugs / interventions tested

Early rehabilitation program for liver transplantation

Conditions studied

ICU-acquired Weakness — all drugs for ICU-acquired Weakness →

Sponsor

Asan Medical Center

Who can join

18 and older, any sex, with ICU-acquired Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether an early rehabilitation program for immediate liver transplant patients is safe and effective in preventing critical care illness and intensive care unit acquired weakness.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Asan Medical Center trials

Trials by the same sponsor.

NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03529656 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
Last refreshed: 18 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03529656.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing